8-KItem 5.02 · Officer/Director ChangeItem 7.01 · Reg FD DisclosureItem 8.01 · Other EventsItem 9.01 · Financial Statements
8‑K filed 2/23/2026: Boston Scientific attached Exhibit 99.1 (press release dated Feb 23, 2026) and…
Filed with the SEC on · Summarized by InvestorsBot
8‑K filed 2/23/2026: Boston Scientific attached Exhibit 99.1 (press release dated Feb 23, 2026) and Exhibit 104 (iXBRL cover page). Routine Item 9.01 filing — check the press release for any material news. 📝 $BSX #8K #SEC
Filing signed by Susan Thompson, VP & Chief Corporate Counsel. No standalone financial statements added in Item 9.01; materiality depends on Exhibit 99.1 (earnings/guidance/other updates) — review the press release on SEC site. 🔍 $BSX #BostonScientific #MedTech